An Vandebosch
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, Hepatitis C virus research, HIV/AIDS drug development and treatment, COVID-19 Clinical Research Studies, Vaccine Coverage and Hesitancy
Most-Cited Works
- → Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19(2021)2,574 cited
- → Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S(2022)249 cited
- → Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin(2012)221 cited
- → Correlation Between Type of Adaptive Immune Response Against Porcine Circovirus Type 2 and Level of Virus Replication(2005)138 cited
- → Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials(2020)114 cited
- → Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial(2022)90 cited
- → Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study(2021)90 cited
- → Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial(2022)86 cited
- → Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate(2020)71 cited
- → Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor(2015)49 cited